Li Kang Biomedical Co Ltd (6242) - Total Assets
Based on the latest financial reports, Li Kang Biomedical Co Ltd (6242) holds total assets worth NT$1.09 Billion TWD (≈ $34.44 Million USD) as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore debt repayment capacity of Li Kang Biomedical Co Ltd to assess how comfortably operating cash covers total debt obligations.
Li Kang Biomedical Co Ltd - Total Assets Trend (2002–2025)
This chart illustrates how Li Kang Biomedical Co Ltd's total assets have evolved over time, based on quarterly financial data. See net assets of Li Kang Biomedical Co Ltd for net asset value and shareholders' equity analysis.
Li Kang Biomedical Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2025)
Li Kang Biomedical Co Ltd's total assets of NT$1.09 Billion consist of 23.2% current assets and 76.9% non-current assets.
| Asset Category | Amount (TWD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | NT$0.00 | 3.9% |
| Accounts Receivable | NT$9.33 Million | 0.9% |
| Inventory | NT$45.79 Million | 4.2% |
| Property, Plant & Equipment | NT$0.00 | 0.0% |
| Intangible Assets | NT$0.00 | 0.0% |
| Goodwill | NT$0.00 | 0.0% |
Asset Composition Trend (2002–2025)
This chart illustrates how Li Kang Biomedical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Li Kang Biomedical Co Ltd market cap and net worth.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Li Kang Biomedical Co Ltd's current assets represent 23.2% of total assets in 2025, an increase from 0.0% in 2002.
- Cash Position: Cash and equivalents constituted 3.9% of total assets in 2025, down from 4.2% in 2002.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2002.
- Asset Diversification: The largest asset category is inventory at 4.2% of total assets.
Li Kang Biomedical Co Ltd Competitors by Total Assets
Key competitors of Li Kang Biomedical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Flight Centre Travel Group Ltd
AU:FLT
|
Australia | AU$4.66 Billion |
|
Corporate Travel Management Ltd
AU:CTD
|
Australia | AU$1.59 Billion |
|
WEB Travel Group Ltd
AU:WEB
|
Australia | AU$1.54 Billion |
|
Helloworld Travel Ltd
AU:HLO
|
Australia | AU$590.94 Million |
|
Jayride Group Ltd
AU:JAY
|
Australia | AU$461.01K |
|
CVC Brasil Operadora e Agencia
SA:CVCB3
|
Brazil | R$4.22 Billion |
|
Transat AT Inc
TO:TRZ
|
Canada | CA$2.87 Billion |
|
Changbai Mountain Tourism Co Ltd
SHG:603099
|
China | CN¥1.82 Billion |
Li Kang Biomedical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.50 | 5.45 | 2.23 |
| Quick Ratio | 1.23 | 4.97 | 1.97 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | NT$84.59 Million | NT$418.66 Million | NT$147.89 Million |
Li Kang Biomedical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Li Kang Biomedical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.38 |
| Latest Market Cap to Assets Ratio | 0.03 |
| Asset Growth Rate (YoY) | 5.5% |
| Total Assets | NT$1.09 Billion |
| Market Capitalization | $34.47 Million USD |
Valuation Analysis
Below Book Valuation: The market values Li Kang Biomedical Co Ltd's assets below their book value (0.03x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Li Kang Biomedical Co Ltd's assets grew by 5.5% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Li Kang Biomedical Co Ltd (2002–2025)
The table below shows the annual total assets of Li Kang Biomedical Co Ltd from 2002 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | NT$1.09 Billion ≈ $34.44 Million |
+5.55% |
| 2024-12-31 | NT$1.04 Billion ≈ $32.63 Million |
+25.22% |
| 2023-12-31 | NT$827.00 Million ≈ $26.06 Million |
+20.06% |
| 2022-12-31 | NT$688.84 Million ≈ $21.70 Million |
+11.81% |
| 2021-12-31 | NT$616.07 Million ≈ $19.41 Million |
-4.45% |
| 2020-12-31 | NT$644.77 Million ≈ $20.31 Million |
+2.93% |
| 2019-12-31 | NT$626.44 Million ≈ $19.74 Million |
+2.72% |
| 2018-12-31 | NT$609.85 Million ≈ $19.21 Million |
+2.31% |
| 2017-12-31 | NT$596.06 Million ≈ $18.78 Million |
+7.44% |
| 2016-12-31 | NT$554.77 Million ≈ $17.48 Million |
+5.32% |
| 2015-12-31 | NT$526.73 Million ≈ $16.59 Million |
+62.38% |
| 2014-12-31 | NT$324.37 Million ≈ $10.22 Million |
+190.16% |
| 2013-12-31 | NT$111.79 Million ≈ $3.52 Million |
-24.24% |
| 2012-12-31 | NT$147.57 Million ≈ $4.65 Million |
-19.28% |
| 2011-12-31 | NT$182.81 Million ≈ $5.76 Million |
+18.73% |
| 2010-12-31 | NT$153.96 Million ≈ $4.85 Million |
-39.10% |
| 2009-12-31 | NT$252.83 Million ≈ $7.97 Million |
-42.39% |
| 2008-12-31 | NT$438.89 Million ≈ $13.83 Million |
-37.47% |
| 2007-12-31 | NT$701.86 Million ≈ $22.11 Million |
-7.36% |
| 2006-12-31 | NT$757.63 Million ≈ $23.87 Million |
-4.23% |
| 2005-12-31 | NT$791.11 Million ≈ $24.92 Million |
+3.23% |
| 2004-12-31 | NT$766.35 Million ≈ $24.14 Million |
-0.49% |
| 2003-12-31 | NT$770.15 Million ≈ $24.26 Million |
+0.55% |
| 2002-12-31 | NT$765.96 Million ≈ $24.13 Million |
-- |
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded i… Read more